Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
Radioiodine therapy for differentiated thyroid cancer has been used for a long time, mainly in patients of intermediate and high risk, as well as in the presence of distant metastases. However, about 30–40 % of patients are refractory to radioiodine therapy, which significantly worsens the prognosis...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-02-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242543544336384 |
|---|---|
| author | E. V. Borodavina V. V. Krylov P. A. Isaev A. Yu. Shurinov A. A. Rodichev |
| author_facet | E. V. Borodavina V. V. Krylov P. A. Isaev A. Yu. Shurinov A. A. Rodichev |
| author_sort | E. V. Borodavina |
| collection | DOAJ |
| description | Radioiodine therapy for differentiated thyroid cancer has been used for a long time, mainly in patients of intermediate and high risk, as well as in the presence of distant metastases. However, about 30–40 % of patients are refractory to radioiodine therapy, which significantly worsens the prognosis. In patients with radioiodine-refractory differentiated thyroid cancer, therapy with targeted agents, primarily tyrosine kinase inhibitors, is indicated.This review addresses the criteria for refractoriness and criteria for prescription of targeted therapy, and presents the results of clinical studies of the targeted agents used. As of today, lenvatinib is the most well-known targeted agent. In particular. In SELECT trial lenvatinib demonstrated efficacy in terms of progression-free survival and overall survival in patients with radioiodine-refractory differentiated thyroid cancer. As a result, lenvatinib was included in the international and Russian clinical guidelines for the management of this group of patients as a drug of the 1st line of targeted therapy. |
| format | Article |
| id | doaj-art-9005fd6e5fff422eb5811e78ac12261f |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2022-02-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-9005fd6e5fff422eb5811e78ac12261f2025-08-20T03:59:48ZrusABV-pressОпухоли головы и шеи2222-14682411-46342022-02-0111411913010.17650/2222-1468-2021-11-4-119-130476Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapyE. V. Borodavina0V. V. Krylov1P. A. Isaev2A. Yu. Shurinov3A. A. Rodichev4A. F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaA. F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaA. F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaA. F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaA. F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaRadioiodine therapy for differentiated thyroid cancer has been used for a long time, mainly in patients of intermediate and high risk, as well as in the presence of distant metastases. However, about 30–40 % of patients are refractory to radioiodine therapy, which significantly worsens the prognosis. In patients with radioiodine-refractory differentiated thyroid cancer, therapy with targeted agents, primarily tyrosine kinase inhibitors, is indicated.This review addresses the criteria for refractoriness and criteria for prescription of targeted therapy, and presents the results of clinical studies of the targeted agents used. As of today, lenvatinib is the most well-known targeted agent. In particular. In SELECT trial lenvatinib demonstrated efficacy in terms of progression-free survival and overall survival in patients with radioiodine-refractory differentiated thyroid cancer. As a result, lenvatinib was included in the international and Russian clinical guidelines for the management of this group of patients as a drug of the 1st line of targeted therapy.https://ogsh.abvpress.ru/jour/article/view/724thyroid cancerradioiodine refractorinesstargeted therapytyrosine kinase inhibitorslenvatinib |
| spellingShingle | E. V. Borodavina V. V. Krylov P. A. Isaev A. Yu. Shurinov A. A. Rodichev Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy Опухоли головы и шеи thyroid cancer radioiodine refractoriness targeted therapy tyrosine kinase inhibitors lenvatinib |
| title | Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy |
| title_full | Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy |
| title_fullStr | Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy |
| title_full_unstemmed | Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy |
| title_short | Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy |
| title_sort | historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer refractory to radioactive iodine therapy |
| topic | thyroid cancer radioiodine refractoriness targeted therapy tyrosine kinase inhibitors lenvatinib |
| url | https://ogsh.abvpress.ru/jour/article/view/724 |
| work_keys_str_mv | AT evborodavina historicalaspectsandmodernconceptsinthetreatmentofpatientswithdifferentiatedthyroidcancerrefractorytoradioactiveiodinetherapy AT vvkrylov historicalaspectsandmodernconceptsinthetreatmentofpatientswithdifferentiatedthyroidcancerrefractorytoradioactiveiodinetherapy AT paisaev historicalaspectsandmodernconceptsinthetreatmentofpatientswithdifferentiatedthyroidcancerrefractorytoradioactiveiodinetherapy AT ayushurinov historicalaspectsandmodernconceptsinthetreatmentofpatientswithdifferentiatedthyroidcancerrefractorytoradioactiveiodinetherapy AT aarodichev historicalaspectsandmodernconceptsinthetreatmentofpatientswithdifferentiatedthyroidcancerrefractorytoradioactiveiodinetherapy |